Conditioned pain modulation is more efficient in patients with painful diabetic polyneuropathy than those with nonpainful diabetic polyneuropathy.

"Conflict of interest statement L. Shafran Topaz, Y. Granovsky, R. Zubiedat, S. Crystal, C. Buxbaum, N. Bosak, R. Hadad, and E. Domany have nothing to disclose. H. Laycock is an editor for Anesthesia, she was part funded by the Horizon 2020 European grant. M. Khamaisi and E. Sprecher have nothing to disclose. D.L. Bennett has acted as a consultant in the past 2 years for Amgen, Bristows, CODA therapeutics, LatigoBio, Lilly, Mundipharma, OliPass, Orion, Regeneron, and Theranexus on behalf of Oxford University Innovation. Additionally, D.L. Bennett has an Industrial Partnership grant with Astra Zeneca funded by the BBSRC. D. Yarnitsky holds shares in BrainsGate and Theranica. A. Rice's conflicts of interest occurring in the past 2 years include consultancy and advisory board work for Imperial College Consultants and remunerated work for Abide, Confo, Vertex, Pharmanovo, Lateral, Novartis, Mundipharma, Orion, Asahi Kasei, Toray, and Theranexis. In addition, A. Rice was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015. The final payment was made in 2019. He is also named as an inventor on patents: (1) Rice A.S.C., Vandevoorde S., and Lambert D.M Methods using N-(2-propenyl) hexadecanamide and related amides to relieve pain. WO 2005/079771 and (2) Okuse K. et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/WO2013 110945. This study is funded by the European Union's Horizon 2020 research and innovation programme No. 633491 (DOLORisk). The collected data are available to all members of the DOLORisk consortium and can be received by contacting the consortium."

"L. Shafran Topaz, Y. Granovsky, R. Zubiedat, S. Crystal, C. Buxbaum, N. Bosak, R. Hadad, and E. Domany have nothing to disclose. H. Laycock is an editor for Anesthesia, she was part funded by the Horizon 2020 European grant. M. Khamaisi and E. Sprecher have nothing to disclose. D.L. Bennett has acted as a consultant in the past 2 years for Amgen, Bristows, CODA therapeutics, LatigoBio, Lilly, Mundipharma, OliPass, Orion, Regeneron, and Theranexus on behalf of Oxford University Innovation. Additionally, D.L. Bennett has an Industrial Partnership grant with Astra Zeneca funded by the BBSRC. D. Yarnitsky holds shares in BrainsGate and Theranica. A. Rice's conflicts of interest occurring in the past 2 years include consultancy and advisory board work for Imperial College Consultants and remunerated work for Abide, Confo, Vertex, Pharmanovo, Lateral, Novartis, Mundipharma, Orion, Asahi Kasei, Toray, and Theranexis. In addition, A. Rice was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015. The final payment was made in 2019. He is also named as an inventor on patents: (1) Rice A.S.C., Vandevoorde S., and Lambert D.M Methods using N-(2-propenyl) hexadecanamide and related amides to relieve pain. WO 2005/079771 and (2) Okuse K. et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/WO2013 110945. This study is funded by the European Union's Horizon 2020 research and innovation programme No. 633491 (DOLORisk). The collected data are available to all members of the DOLORisk consortium and can be received by contacting the consortium."